Point72 Asset Management
VIGL

Point72 Asset Management’s Vigil Neuroscience VIGL Stock Holding History

Point72 Asset Management’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-250,000
Closed -$425K – 2571
2024
Q4 		$425K Sell
250,000
-1,350,000
-84% -$3.99M ﹤0.01% 1708
2024
Q3 		$5.44M Buy
1,600,000
+115,000
+8% +$426K 0.01% 863
2024
Q2 		$5.94M Buy
+1,485,000
New +$5.08M 0.02% 790

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Point72 Asset Management's VIGL Position: Q1 2025 in Review

Point72 Asset Management sold out of Vigil Neuroscience (VIGL) in Q1 2025, closing a stake of 250,000 shares — an estimated $425K sold.

Point72 Asset Management first reported a position in VIGL in Q2 2024 and held it in 3 quarters. The position peaked at $5.94M in Q2 2024. 50 funds tracked by Wall St. Rank hold VIGL as of Q1 2025.

  • Point72 Asset Management reported no remaining Vigil Neuroscience position as of Q1 2025 after selling out during the quarter.
  • Point72 Asset Management sold 250,000 Vigil Neuroscience shares in Q1 2025, an estimated $425K.
  • Point72 Asset Management first reported a position in Vigil Neuroscience in Q2 2024 and held it in 3 quarters.
  • Point72 Asset Management's Vigil Neuroscience position peaked at $5.94M in Q2 2024.
  • 50 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q1 2025.

Based on Point72 Asset Management's 13F filing for Q1 2025, filed 15 May 2025.